TY  - BOOK
AU  - Gemma,Akihiko
ED  - SpringerLink (Online service)
TI  - Analysis File of Drug-Induced Lung Injury: Expert Opinion for Analysis of Big Data 
SN  - 9789819734467
AV  - RC705-779 
PY  - 2024///
CY  - Singapore
PB  - Springer Nature Singapore, Imprint: Springer
KW  - Respiratory organs
KW  - Diseases
KW  - Medical genetics
KW  - Causes and theories of causation
KW  - Oncology
KW  - Pharmacology
KW  - Genetics
KW  - Research
KW  - Pneumology
KW  - Clinical Genetics
KW  - Pathogenesis
KW  - Genetics Research
N1  - Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)
N2  - This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies
UR  - https://doi.org/10.1007/978-981-97-3446-7
ER  -